Cannabis Science Inc  

(Public, OTCMKTS:CBIS)   Watch this stock  
Find more results for PINK:CBIS
0.0000 (0.00%)
Nov 30 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.01 - 0.08
Open     -
Vol / Avg. 0.00/7.41M
Mkt cap 26.04M
P/E     -
Div/yield     -
EPS -0.02
Shares 1.30B
Beta 1.47
Inst. own 0%

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -1639297.00%
Operating margin - -1551864.00%
EBITD margin - -995567.90%
Return on average assets -1790.59% -1723.57%
Return on average equity - -
Employees 5 -
CDP Score - -


Suite B #254, 6946 North Academy Blvd
United States - Map
+1-888-8890888 (Phone)


Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science focusing critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company's goal is the development of governmentally approved pharmaceuticals, including the aforementioned CS-TATI1, CS-S/BCC-1, and patented neurological therapy under study or development. The Company has two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV. The Company has partnered with propagators and laboratories for extractions, analytical development and clinical trial implementation.

Officers and directors

Raymond C Dabney Chief Executive Officer, Director
Age: 50
Robert Kane Chief Financial Officer, Director
Age: 39
Chad S Johnson Esq. Chief Operating Officer, General Legal Counsel, Director
Age: 46
Richard Ogden Chief Scientific Officer
Age: 60
Allen A. Herman Chief Medical Officer
Mario Lap Director
Age: 63